Top Suppliers:I want be here
Related CAS#:
1607431-21-9 1310726-60-3
102043-41-4 152854-19-8
30903-88-9 245759-62-0
1204130-47-1 22719-15-9
302-31-8 2407529-33-1

1607431-21-9

1607431-21-9 structure
1607431-21-9 structure
  • Name: Upadacitinib tartrate
  • Chemical Name: Upadacitinib tartrate
  • CAS Number: 1607431-21-9
  • Molecular Formula: C21H33F3N6O11
  • Molecular Weight: 602.516
  • Catalog: Signaling Pathways Epigenetics JAK
  • Create Date: 2018-07-18 22:43:58
  • Modify Date: 2024-01-04 17:09:18
  • Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research[1][2].
Name Upadacitinib tartrate
Synonyms Upadacitinib tartrate
(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate, tetrahydrate
(2R,3R)-2,3-Dihydroxysuccinic acid - (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide hydrate (1:1:4)
Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide, hydrate (1:1:4)
ABT-494
UNII-7KCW9IQM02
Description Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research[1][2].
Related Catalog
Target

JAK1:0.043 μM (IC50)

JAK2:0.2 μM (IC50)

JAK3:2.3 μM (IC50)

Tyk2:4.7 μM (IC50)
In Vitro In biochemical assays, Upadacitinib tartrate tetrahydrate is 74-fold more selective for JAK-1 than for JAK-2 (which is involved in erythropoiesis) and 58-fold more selective for JAK-1 than for JAK-3 (which is involved in immunosurveillance)[1].
In Vivo Upadacitinib (0.1-10 mg/kg; oral gavage; twice a day for 10 days) tartrate tetrahydrate demonstrates efficacy in rat arthritis models[3]. Animal Model: Female Lewis rats (Rat adjuvant-induced arthritis model)[3] Dosage: 0.1, 0.3, 1, 3, 10 mg/kg Administration: Oral gavage; twice a day for 10 days Result: Inhibited disease pathology in rat adjuvant induced arthritis.
References

[1]. Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419.

[2]. J. Voss, et al. THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects. doi 10.1136/annrheumdis-2014-eular.3823.

[3]. Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23.
Molecular Formula C21H33F3N6O11
Molecular Weight 602.516
Exact Mass 602.215942

Chemsrc provides CAS#:1607431-21-9 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 1607431-21-9 | Chemsrc address: https://m.chemsrc.com/en/baike/1526539.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved